Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of [18F]CSB-321 PET Imaging in Cancer Immunotherapy
NCT07057349Phase 1Not yet recruiting
- Sponsor
- CytoSite Bio
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [18F]CSB-321 in cancer, solid tumor and Uveal melanoma (UM), sponsored by CytoSite Bio. Primary endpoints: Number of clinically significant changes and Frequency and grade of adverse events due to [18F]CSB-321. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
[18F]CSB-321
03
Conditions
cancersolid tumorUveal melanoma (UM)
Beyond the preview
Go deeper on NCT07057349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07057349.